Ningning Xue

Ningning Xue

Auto-generated profile, based on publicly available information

Ningning Xue

Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
DZDandan Zhao
Dandan Zhao
SYSonghao Yu
Songhao Yu
PGPeilin Guo
Peilin Guo
XZXiaoxiao Zhang
Xiaoxiao Zhang
YTYuhui Tang
Yuhui Tang
YNYuemin Nan
Yuemin Nan

29 April 2022 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
WLWencong Li
Wencong Li
JLJing Liang
Jing Liang
JAJihong An
Jihong An
LLLingdi Liu
Lingdi Liu
YHYihui Hou
Yihui Hou
LZLiaoyun Zhang
Liaoyun Zhang
Objective. To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods. The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. Results. Four genotypes and six subtypes were identified as follows: 1b (1187, 54.90%), 2a (790, 36.54%), 3a/b (134, 6.20%), 6a/n (44, 2.04%), mixed genotypes (2a-6a or 2a-3a) (7, 0.32%). Overall, 99.01% patients achieved SVR12, while 98.43% achieved SVR24. All patients treated with elbasvir/grazoprevir (EBR/GZR), sofosbuvir/velpatasvir ± ribavirin (SOF/VEL ± RBV), and SOF/ledipasvir (LDV) achieved SVR12 or SVR24; 92.86% SVR12 and 95.83% SVR24 were observed in patients using SOF + RBV. SVR12 was higher in noncirrhosis versus compensated cirrhosis patients (100% vs. 97.09%, ). No severe drug-related adverse event was observed. Conclusions. Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile.

17 September 2021 in Biomarkers in Medicine
Verified
Journal Article
Closed access
WZWen Zhao
Wen Zhao
NXNingning Xue
Ningning Xue
PCPo Cui
Po Cui
LLLingdi Liu
Lingdi Liu
YWYiqi Wang
Yiqi Wang
YNYuemin Nan
Yuemin Nan
Aim: To explore the predictive value of plasma YAP1 for esophageal varices (EV) and high-risk EV (HRV) in patients with liver cirrhosis. Materials & methods: A total of 208 patients with liver cirr...